Rhythm Pharmaceuticals (RYTM) Change in Acquisitions & Divestments (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Change in Acquisitions & Divestments data on file, last reported at $99.3 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $99.3 million, up 70.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $293.4 million (up 17.86% YoY), and the FY2025 annual result was $252.5 million, down 3.13% from the prior year.
• Change in Acquisitions & Divestments grew to $99.3 million in Q1 2026 per RYTM's latest filing, from $51.6 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $124.5 million in Q2 2023 and troughed at $45.3 million in Q3 2024.
• A 5-year average of $73.6 million and a median of $63.3 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments plunged 60.76% in 2022, then jumped 144.12% in 2023.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $59.6 million in 2022, then advanced by 6.12% to $63.3 million in 2023, then jumped by 38.3% to $87.5 million in 2024, then slumped by 41.0% to $51.6 million in 2025, then surged by 92.17% to $99.3 million in 2026.
• Business Quant data shows RYTM's Change in Acquisitions & Divestments at $99.3 million in Q1 2026, $51.6 million in Q4 2025, and $61.5 million in Q3 2025.